Eliem Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 10.55 million compared to USD 14.86 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 4.99 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.415 USD | -6.69% | -18.30% | +26.48% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+26.48% | 103M | |
-2.28% | 104B | |
+1.42% | 97.42B | |
+0.79% | 22.2B | |
-17.83% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.70% | 15.06B | |
+4.31% | 13.98B | |
+32.05% | 11.66B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021